EBITDA: Income before interest, taxes, depreciation and amortization.
Cadrenal Therapeutics, Inc. (CVKD) had EBITDA of $-3.06M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-3.04M |
|
-- |
|
-- |
|
$3.07M |
|
$-3.07M |
|
$0.03M |
|
$-3.04M |
|
$-3.04M |
|
$-3.04M |
|
$-3.04M |
|
$-3.04M |
|
$-3.04M |
|
$-3.07M |
|
|
EBITDA |
$-3.06M |
1.99M |
|
1.99M |
|
$-1.37 |
|
$-1.37 |
|
| Balance Sheet Financials | |
$4.32M |
|
$0.01M |
|
$0.01M |
|
$4.33M |
|
$1.59M |
|
-- |
|
-- |
|
$1.59M |
|
$2.74M |
|
$2.74M |
|
$2.74M |
|
2.34M |
|
| Cash Flow Statement Financials | |
$-12.60M |
|
$-0.01M |
|
$6.60M |
|
$10.02M |
|
$4.01M |
|
$-6.01M |
|
$1.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.61M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-110.96% |
|
-110.96% |
|
-70.24% |
|
-110.96% |
|
$1.17 |
|
$-6.32 |
|
$-6.32 |
|